- Previous Close
1.8200 - Open
1.7700 - Bid 1.7600 x --
- Ask 1.7800 x --
- Day's Range
1.7000 - 1.8000 - 52 Week Range
1.5000 - 3.4300 - Volume
32,942 - Avg. Volume
36,757 - Market Cap (intraday)
81.844M - Beta (5Y Monthly) 1.73
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0600 - Earnings Date Oct 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.01
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
www.theratech.com103
Full Time Employees
November 30
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: TH.TO
View More
Performance Overview: TH.TO
Trailing total returns as of 2024-11-08, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TH.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TH.TO
View MoreValuation Measures
Market Cap
83.68M
Enterprise Value
110.15M
Trailing P/E
--
Forward P/E
18.69
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.70
Price/Book (mrq)
--
Enterprise Value/Revenue
0.94
Enterprise Value/EBITDA
6.83
Financial Highlights
Profitability and Income Statement
Profit Margin
-3.75%
Return on Assets (ttm)
11.76%
Return on Equity (ttm)
--
Revenue (ttm)
84.32M
Net Income Avi to Common (ttm)
-3.16M
Diluted EPS (ttm)
-0.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
38.86M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.6M